SS Innovations International earnings release, May 13, 2026

SS Innovations International, Inc. (SSII) · Form 8-K, Item 2.02 · Filed · SEC filing

SS Innovations Reports First Quarter 2026 Financial

Results

Record quarterly revenue driven by strong growth in SSi Mantra installations and procedures

Fort Lauderdale, FL – May 13, 2026 – SS Innovations International, Inc.

(the “Company” or “SS Innovations”)

(Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three months ended March 31, 2026. The Company also filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, with the Securities and Exchange Commission on May 13, 2026.

First Quarter 2026 Overview

As of March 31, 2026

CEO Commentary

Dr. Sudhir Srivastava, Chairman of the Board and

Chief Executive Officer of SS Innovations, commented, “In the first quarter of 2026 we reported record quarterly revenue of $11.1 million, up 117% year over year, driven by robust growth in SSi Mantra installations and procedures. Strong adoption by hospitals and physicians reflects the SSi Mantra’s cutting-edge surgical robotic technology, differentiated features, user friendliness, training capabilities, and cost efficiency. Among other developments in the quarter, we received regulatory approval for the SSi Mantra for multiple indications in Sri Lanka and Kenya and for telesurgery in Indonesia and the Philippines. We also successfully completed a private placement in March 2026 that provided SS Innovations with approximately $18.6 million in gross proceeds to fuel growth initiatives.”

Dr. Srivastava continued, “Looking ahead, we aim to fortify our position as a leader in the substantial Indian market, expand our global footprint in underserved countries, and secure entry into the United States and European Union markets. We expect the U.S. Food and Drug Administration to complete its review of our 510(k) premarket notification for the SSi Mantra this year. Separately, we continue along the pathway towards a European Union

CE marking certification for the SSi Mantra, which we believe we can also obtain in 2026. We are very excited about the growth runway ahead and remain steadfast in our commitment to democratizing access to advanced surgical robotic care.”

Select Business Highlights in First Quarter

2025

Revenue Breakdown and Summary of Installations

/ Surgeries²

About SS Innovations

SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra

The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana Tele Surgeon

Console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that provides equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 170 different types of surgical procedures.

Forward Looking Statements

This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.

The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,”

“intend,” “may,” “plan,” “project,” “should,” “could,” “seek,”

Financial statements

Income Statement

Revenue Breakdown and Summary of Installations / Surgeries

Q1 2025Q1 2026VariancePercentage
System sales4,502,4829,575,3705,072,888112.7%
Instrument sales477,2081,151,228674,020141.2%
Warranty sales122,504357,686235,182192.0%
Lease income18,41617,082-1,334-7.2%
Total revenue5,120,61011,101,3665,980,756116.8%
SSi Mantra installations15261173.3%
Cumulative installed base178194116148.7%
SSi Mantra surgeries7871,8591,072136.2%
Cumulative surgeries13,5689,7446,176173.1%

Income Statement

For The Three months ended — (Unaudited)

For The Three months ended – March 31, 2026For The Three months ended – March 31, 2025
REVENUESSystem sales9,575,3704,502,482
REVENUESInstruments sale1,151,228477,208
REVENUESWarranty sale357,686122,504
REVENUESLease income17,08218,416
REVENUESTotal revenue11,101,3665,120,610
REVENUESCost of revenue-5,774,145-4,033,402
REVENUESGROSS PROFIT5,327,2211,087,208
OPERATING EXPENSES:Research & development expense995,4401,010,095
OPERATING EXPENSES:Stock compensation expense3,144,3152,379,212
OPERATING EXPENSES:Depreciation and amortization expense323,747208,882
OPERATING EXPENSES:Selling, general and administrative expense4,502,4763,410,872
OPERATING EXPENSES:TOTAL OPERATING EXPENSES8,965,9787,009,061
OPERATING EXPENSES:Loss from operations-3,638,757-5,921,853
OTHER INCOME (EXPENSE):Interest Expense-284,051-379,905
OTHER INCOME (EXPENSE):Interest and other income, net491,589620,405
OTHER INCOME (EXPENSE):TOTAL INCOME, NET207,538240,500
OTHER INCOME (EXPENSE):LOSS BEFORE INCOME TAXES-3,431,219-5,681,353
OTHER INCOME (EXPENSE):Income tax expense151,352
OTHER INCOME (EXPENSE):NET LOSS-3,582,571-5,681,353
CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE LOSSNET LOSS-3,582,571-5,681,353
OTHER COMPREHENSIVE INCOME (LOSS):Foreign currency translation loss-1,557,1116,876
OTHER COMPREHENSIVE INCOME (LOSS):Retirement Benefit4,78115,838
RECLASSIFICATION ADJUSTMENTS:Retirement Benefit (1)3,056
RECLASSIFICATION ADJUSTMENTS:Income tax effects relating to retirement benefit-1,203
RECLASSIFICATION ADJUSTMENTS:TOTAL OTHER COMPREHENSIVE LOSS-1,550,47722,714
RECLASSIFICATION ADJUSTMENTS:TOTAL COMPREHENSIVE LOSS-5,133,048-5,658,639

Balance Sheet

(Unaudited)

As of – March 31, 2026As of – December 31, 2025
Current Assets:Cash and cash equivalents15,979,7143,206,406
Current Assets:Restricted cash7,631,3365,937,650
Current Assets:Accounts receivable, net14,054,37612,398,542
Current Assets:Inventory17,066,09117,064,002
Current Assets:Prepaids and other current assets11,530,00010,166,823
Current Assets:Total Current Assets66,261,51748,773,423
Current Assets:Property, plant, and equipment, net8,831,4239,100,546
Current Assets:Right of use asset, net2,499,4902,754,020
Current Assets:Deferred tax assets, net805,750533,727
Current Assets:Accounts receivable, net-non current7,265,9118,566,654
Current Assets:Restricted cash- non current394,630458,964
Current Assets:Prepaids and other non current assets4,488,1684,038,883
Current Assets:Total Assets90,546,88974,226,217
Current LiabilitiesBank overdraft facility11,156,14711,442,948
Current LiabilitiesCurrent portion of operating lease liabilities576,237579,169
Current LiabilitiesAccounts payable4,403,1705,127,193
Current LiabilitiesDeferred revenue3,582,6313,266,686
Current LiabilitiesAccrued expenses & other current liabilities6,326,8185,825,702
Current LiabilitiesTotal Current Liabilities26,045,00326,241,698
Current LiabilitiesOperating lease liabilities, less current portion2,086,5342,337,697
Current LiabilitiesDeferred Revenue- non current7,501,2837,139,807
Current LiabilitiesOther non current liabilities390,656288,764
Current LiabilitiesTotal Liabilities36,023,47636,007,966
Stockholders’ equity:Preferred stock, authorized 5,000,000 shares of Series A, Non-Convertible Preferred Stock, $0.0001 par value per share; 1,000 shares issued and outstanding as of March 31, 2026, and December 31, 202511
Stockholders’ equity:Common stock, 250,000,000 shares authorized, $0.0001 par value, 200,131,535 shares and 194,165,141 shares issued and outstanding as of March 31, 2026 and December 31, 2025 respectively20,01319,416
Stockholders’ equity:Accumulated other comprehensive income (loss)-3,573,137-2,022,660
Stockholders’ equity:Additional paid in capital116,549,12495,111,511
Stockholders’ equity:Capital reserve899,917899,917
Stockholders’ equity:Accumulated deficit-59,372,505-55,789,934
Stockholders’ equity:Total stockholders’ equity54,523,41338,218,251
Stockholders’ equity:Total liabilities and stockholders’ equity90,546,88974,226,217

Cash Flow

For The Three months ended — (Unaudited)

For The Three months ended – March 31, 2026For The Three months ended – March 31, 2025
Cash flows from operating activities:Net loss-3,582,571-5,681,353
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization323,747208,882
Adjustments to reconcile net loss to net cash used in operating activities:Operating lease expense220,493205,275
Adjustments to reconcile net loss to net cash used in operating activities:Interest Expense43,555155,015
Adjustments to reconcile net loss to net cash used in operating activities:Interest and other income, net-415,465-140,928
Full release

“designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:

The Equity Group

Kalle Ahl, CFA

T: (303) 953-9878 kahl@theequitygroup.com

Devin Sullivan, Managing Director

T: (212) 836-9608 dsullivan@theequitygroup.com

Media Contact:

RooneyPartners LLC

Kate Barrette

T: (212) 223-0561 kbarrette@rooneypartners.com³

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · SS Innovations International earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.